Re: Breast cancer and Atrophic Vaginitis

From: Larry Glazerman (l.glazerman@rcn.com)
Wed May 4 16:39:02 2005


I'd seriously consider Vagifem (no evidence of systemic absorption)

--
Larry R. Glazerman, MD
Ob-Gyn at Trexlertown, PC
610-402-0161
l.glazerman@rcn.com

_____

From: ob-gyn-l@obgyn.net [mailto:ob-gyn-l@obgyn.net] On Behalf Of Henry Gregor Sent: Wednesday, May 04, 2005 3:45 PM To: Multiple recipients of list OB-GYN-L Subject: Re: Breast cancer and Atrophic Vaginitis

To All,

I have a 66 yo, s/p NIH treatment in 10/02 for inflammatory breast CA Stage III B, with right modified radical mastectomy, with ER/PR negative markers, and HER-2 negative results. Underwent a 15 treatment protocol of a NIH pilot study of Bevacizumab (monoclonal antibody), adriamycin, and Taxotere. 4 of 19 nodes positive. Pt also underwent post-surgery radiation therapy. She is currently on Arimidex. (Pt had been on Evista before her tumor dx.)

Replens, AstroGel, KY jelly have not been helpful to her for relief of very symptomatic atrophic vaginitis. Any suggestion would be appreciated. Thanks.

Hank _____

Yahoo! Mail Stay connected, organized, and protected. Take the tour





use when must restrict search to only the ob-gyn-l forum...
Enter search keywords:
Returns per screen: Require all keywords:

Return to  OB-GYN-L Mail a New Message to the Forum: ob-gyn-l@obgyn.net
Forum Administrator: geffrey.klein@obgyn.net
Report Technical Problems: webmaster@obgyn.net
Last Updated: Wed Jul 2 04:39:35 2008

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.